JP2022513437A5 - - Google Patents

Info

Publication number
JP2022513437A5
JP2022513437A5 JP2021529785A JP2021529785A JP2022513437A5 JP 2022513437 A5 JP2022513437 A5 JP 2022513437A5 JP 2021529785 A JP2021529785 A JP 2021529785A JP 2021529785 A JP2021529785 A JP 2021529785A JP 2022513437 A5 JP2022513437 A5 JP 2022513437A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding fragment
monoclonal antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021529785A
Other languages
English (en)
Japanese (ja)
Other versions
JP7478149B2 (ja
JP2022513437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063729 external-priority patent/WO2020113084A1/en
Publication of JP2022513437A publication Critical patent/JP2022513437A/ja
Publication of JP2022513437A5 publication Critical patent/JP2022513437A5/ja
Application granted granted Critical
Publication of JP7478149B2 publication Critical patent/JP7478149B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021529785A 2018-11-28 2019-11-27 治療用第xii因子抗体 Active JP7478149B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862772235P 2018-11-28 2018-11-28
US62/772,235 2018-11-28
PCT/US2019/063729 WO2020113084A1 (en) 2018-11-28 2019-11-27 Therapeutic factor xii antibody

Publications (3)

Publication Number Publication Date
JP2022513437A JP2022513437A (ja) 2022-02-08
JP2022513437A5 true JP2022513437A5 (enExample) 2022-09-29
JP7478149B2 JP7478149B2 (ja) 2024-05-02

Family

ID=69024611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529785A Active JP7478149B2 (ja) 2018-11-28 2019-11-27 治療用第xii因子抗体

Country Status (5)

Country Link
US (1) US12134657B2 (enExample)
EP (1) EP3886982A1 (enExample)
JP (1) JP7478149B2 (enExample)
CN (1) CN113423465B (enExample)
WO (1) WO2020113084A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230035355A (ko) * 2020-07-03 2023-03-13 씨에스엘 이노베이션 피티와이 엘티디 인자 xii 항원 결합 단백질의 고농도 제형
CN116265945B (zh) * 2022-01-05 2025-12-09 上海迈晋生物医药科技有限公司 抗凝血药物的生物学活性检测方法
CN121358781A (zh) * 2023-06-16 2026-01-16 江苏贝捷泰生物科技有限公司 特异性识别因子XIIa的抗体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
WO2003013423A2 (en) 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
CA2591786C (en) * 2004-12-23 2013-07-16 Bernhard Nieswandt Prevention of thrombus formation and/or stabilization
CN202179824U (zh) 2011-07-22 2012-04-04 北京美亚视景创恒科技有限公司 数字健身设备集群系统
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
US9574013B2 (en) 2012-12-07 2017-02-21 Vanderbilt University Antibodies against factor XII and uses thereof
JP7109160B2 (ja) * 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第xii因子インヒビターを使用する療法

Similar Documents

Publication Publication Date Title
ES2595091T3 (es) Composiciones farmacéuticas con resistencia a CEA soluble
JP2023002615A5 (enExample)
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP2021530251A (ja) 新規な抗体ならびにそれを調製および使用するための方法
MX2010013236A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2010011955A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP2018531219A (ja) Pd−l1抗体
JP2018531219A6 (ja) Pd−l1抗体
TW202126693A (zh) 標靶bcma的抗體、雙專一性抗體及其用途
JP2021510736A5 (enExample)
RU2009123409A (ru) Новые антипролиферативные антитела
JP2024504390A5 (enExample)
JP2020522488A5 (enExample)
JP2022513437A5 (enExample)
JP2024514109A (ja) 抗cntn4抗体及びその使用
CN117279950B (zh) 一种靶向il-18bp的抗体及其应用
JP2023511963A5 (enExample)
JP2018528759A5 (enExample)
CN114591434A (zh) 抗Siglec15抗体及其制备方法和用途
JP2019510474A (ja) トロンビン抗体、その抗原結合フラグメント及び医薬用途
JP2026027248A (ja) 抗原結合分子およびその使用
JP2024542944A5 (enExample)
US20250161441A1 (en) Medicine comprising combination of anti-mutant-calr antibody and another drug
CN120187752A (zh) 人源化的l1cam抗体药物偶联物
JP2024547122A5 (enExample)